Finally a breakthrough in lasting relief for dry eye patients

For millions of people, dry eye disease is more than just a daily annoyance—it’s a constant battle with burning, watering, blurred vision and the feeling of grit or sand in the eye. The condition has  steadily become more common, especially with increased screen time and aging.

Most dry eye sufferers are familiar with artificial tears, warm compresses or prescription eye drops. While these treatments can help, they only offer short-term relief, because they don’t address the root of the problem, which is inflammation and clogged meibomian glands. These glands produce the protective oil layer of your tears, and when they become blocked or damaged—something that happens in the majority of dry eye cases—the tear film evaporates too quickly, leaving the eyes exposed and irritated.

Eye care specialists have been searching for treatments that extend beyond simple, temporary relief. One of the most promising of those advancements is OptiLight, the first and only FDA-approved IPL (Intense Pulsed Light) therapy specifically designed for dry eye disease caused by meibomian gland dysfunction (MGD).

What Makes OptiLight Different

OptiLight uses gentle pulses of light applied around the eyes—not on the eyes themselves—to target the underlying inflammation that contributes to MGD and dry eye disease. This broad-spectrum light helps:

• Reduce inflammation on the skin and eyelids
• Unclog and improve function of the meibomian glands
• Decrease bacteria and Demodex mites that irritate the eyelids
• Stabilize the tear film, reducing evaporation
• Improve natural oil production, boosting long-term comfort

Unlike eyedrops that must be used daily, OptiLight is performed in-office in a series of quick treatments, typically bimonthly, for four sessions. Most patients describe the sensation as warm and gentle with minimal downtime.

Clinical studies show that patients notice improvements after just a couple of sessions and experience relief that lasts. Because OptiLight addresses inflammation and gland dysfunction directly, results tend to last longer than temporary therapies. Benefits often include:

• Less burning and watering
• Fewer blurry-vision episodes
• Reduced dependence on artificial tears
• Greater comfort during screen use
• Healthier, more functional meibomian glands

(Many patients choose maintenance treatments every 6–12 months to keep symptoms under control.)

Who Is a Good Candidate?

A comprehensive dry eye evaluation helps determine the best treatment plan.

OptiLight may be ideal for dry eye patients who:

• Have been diagnosed with meibomian gland dysfunction
• Struggle with chronic irritation despite drops or compresses
• Experience eyelid inflammation, redness, or rosacea
• Want a non-invasive, drug-free option for relief

OptiLight’s modern technology and ability to treat the root causes of MGD—not just the symptoms—is helping patients finally experience the comfort and clarity they’ve been missing and offering new hope.

Dry eye disease can significantly impact quality of life. Call Jones Optical at (217) 359-2390 for a free consultation to determine whether OptiLight is the right option for you and experience a positive life change.